This study aimed to evaluate the dose–response relationship and survival outcomes of iodine-125 seed implantation in patients with advanced lung cancer, focusing on the impact of different dose levels on tumor control and patient prognosis. A retrospective analysis was conducted on 49 patients with advanced lung cancer who underwent iodine-125 seed implantation between January 2017 and March 2021. The patients were divided based on postoperative D90 dose levels, and tumor control rates, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), were assessed. The objective response rate (ORR) and disease control rate (DCR) were also evaluated. Survival analysis was performed to identify prognostic factors. The optimal D90 cutoff values for CR, ORR, and DCR were 136.46 Gy, 121.98 Gy, and 111.47 Gy, respectively. Higher D90 doses were significantly associated with improved tumor control rates (P < 0.05). The 3-year survival rate was 20.41%, with complete response (CR) and preoperative hemoglobin levels identified as independent prognostic factors for long-term survival. Iodine-125 seed implantation demonstrates a clear dose–response relationship in advanced lung cancer, with higher D90 doses correlating with better tumor control. CR and hemoglobin levels are critical factors influencing long-term survival outcomes.
Cao et al. (Fri,) studied this question.